2 min read
Post-Marketing Surveillance in the Philippines is a Regulatory activity mandated to ensure the ongoing quality, safety, and efficacy of health products including medicines, medical devices, and cosmetics after they have been approved and released to the market. PMS is part of a broader pharmacovigilance framework and is enforced by the Philippines Food and Drug Administration (FDA).
What is Post-Marketing Surveillance (PMS)?
- Definition: PMS is the systematic monitoring, data collection, and analysis of products in the market, with the primary goals of identifying safety signals, quality defects, unexpected adverse effects, and Regulatory compliance issues.
- Purpose: It aims to protect public health by ensuring continued benefit-risk assessment of marketed health products. PMS enables the early detection of problems and facilitates regulatory interventions such as advisories, recalls, and labeling changes.
Regulatory Framework in the Philippines
- Legal Basis: Republic Act No. 9711 (FDA Act of 2009) assigns the FDA the mandate to continually ensure post-market surveillance activities.
- Guiding Documents: Administrative Orders and FDA Circulars detail PMS requirements, adverse event reporting, and the implementation of risk minimization measures.
FDA Philippines Post-Marketing Surveillance: Core Obligations and Responsibilities
| Category | FDA's Duties and Actions |
| System Development | Establish and update the national PMS framework, SOPs, and data reporting systems. |
| Market Monitoring | Perform product sampling, market testing, establishment inspections, and audit post-market studies. |
| Adverse Event Surveillance | Collect, evaluate, and act on reports of Adverse Drug Reactions (ADRs) and product complaints from MAHs and the public. |
| Enforcement Actions | Issue public advisories, require recalls, or withdraw hazardous products from the market; impose sanctions for non-compliance. |
| Industry Oversight | Require Market Authorization Holders (MAHs) to submit Periodic Safety Update Reports (PSURs) and participate in PMS activities. |
| Regional Coordination | FDA participates in PMAS (Post-Marketing Alert System) for information exchange information on unsafe or defective products. |
| Clinical/Follow-Up Studies | For certain products (especially monitored release/new drugs), implement and oversee post-market clinical or non-interventional studies. |
Reporting & Market Authorization Holder (MAH) Compliance Requirements
- Adverse Event Reporting Philippines: MAHs must collect and report all serious and non-serious adverse events & product complaints as per defined timelines and formats.
- Periodic Reports: Routine submission of PSURs.
- Immediate Notification: Any product defect, batch-level recall, or international regulatory action must be promptly reported to the FDA.
- Cooperation in Investigations: MAHs must support further studies, safety audits, and risk minimization procedures as required by the FDA.
Special Case: New Drugs/Monitored Release
- Newly registered products placed under monitored release are subject to enhance post-marketing surveillance requirements during the monitored release period.
Summary
- Post-Marketing Surveillance in the Philippines is the FDA's system for continuously evaluating the safety, quality, and performance of health products after approval, helping ensure ongoing public health protection and regulatory compliance.
- The FDA’s PMS obligations include policy-making, sampling and testing, adverse event monitoring, enforcement actions, and international collaboration.
- Market Authorization Holders must establish PMS systems, report all adverse events, and satisfy all regulatory compliance requirements.
Click here to know more about our services: Medicinal Products Regulatory Support in Philippines | Freyr - Global Regulatory Solutions and Services Company
To learn more about how Freyr can support your Regulatory needs in Philippines write to us at sales@freyrsolutions.com.